 |
2 Diseases |  |
32 Trials |
|
32 Trials |  |
1662 News |  |
| «12345678910111213...2425» |
- | Prevymis (letermovir) / Merck (MSD)
Journal: Effect of letermovir initiation on tacrolimus concentrations among lung transplant recipients receiving concomitant azole antifungal prophylaxis. (Pubmed Central) - Mar 15, 2024
Empiric FK dose adjustments do not appear warranted before letermovir initiation in lung transplant recipients receiving antifungal prophylaxis with moderate-to-strong CYP3A4 inhibitors.
- | Prevymis (letermovir) / Merck (MSD)
New trial: Observational Clinical Study of Letermovir for Preventing CMV Infection After Allo-HSCT (clinicaltrials.gov) - Mar 12, 2024
P=N/A, N=150, Recruiting, Sponsor: Cao Weijie
- Prevymis (letermovir) / Merck (MSD), Zepatier (grazoprevir/elbasvir) / Merck (MSD), Crixivan (indinavir sulfate) / Merck (MSD)
Discovery and development of MK-7845 as an investigational treatment for COVID-19 (Hybrid; Room 346 (Ernest N. Morial Convention Center)) - Mar 12, 2024 - Abstract #ACSSp2024ACS_Sp_2199;
Empiric FK dose adjustments do not appear warranted before letermovir initiation in lung transplant recipients receiving antifungal prophylaxis with moderate-to-strong CYP3A4 inhibitors. This commitment has remained strong, as evidenced by the introduction of Crixivan
- | Prevymis (letermovir) / Merck (MSD)
Trial completion date, Trial primary completion date: Letermovir for CMV Prevention After Lung Transplantation (clinicaltrials.gov) - Mar 5, 2024
P2, N=30, Recruiting, Sponsor: Fernanda P Silveira, MD, MS
This commitment has remained strong, as evidenced by the introduction of Crixivan Trial completion date: Jul 2024 --> Jul 2025 | Trial primary completion date: Jul 2024 --> Jul 2025
- | Prevymis (letermovir) / Merck (MSD), Cytovene (ganciclovir) / Roche
Journal: Human neural progenitor cell models to study the antiviral effects and neuroprotective potential of approved and investigational human cytomegalovirus inhibitors. (Pubmed Central) - Mar 4, 2024
Treatment with antiviral drugs had different effects on HCMV-induced dysregulation of the genes under investigation. This study contributes to the understanding of the molecular mechanisms of cCMV neuropathogenesis and paves the way for further consideration of anti-HCMV drugs as candidate therapeutic agents for the amelioration of cCMV-associated neurological manifestations.
- | Journal: Current and Emerging Antiviral Agents in the Prevention and Treatment of Cytomegalovirus in Pediatric Transplant Recipients. (Pubmed Central) - Feb 28, 2024
Maribavir is approved for the treatment of refractory or resistant CMV disease in HCT and SOT recipients ?12 years of age, though it has no current role in CMV prevention. More research is needed to fully elucidate the roles, efficacy, and safety of these newer agents in prevention and treatment of CMV in pediatric transplant recipients.
- | Prevymis (letermovir) / Merck (MSD), Livtencity (maribavir) / Takeda, GSK
Journal: The changing landscape of infections in the lung transplant recipient. (Pubmed Central) - Feb 27, 2024
More research is needed to fully elucidate the roles, efficacy, and safety of these newer agents in prevention and treatment of CMV in pediatric transplant recipients. Although new vaccines and novel therapies for preventing and treating infections are available, larger studies evaluating efficacy in lung transplant recipients are needed.
- || Review, Journal: Human Cytomegalovirus (HCMV) Genetic Diversity, Drug Resistance Testing and Prevalence of the Resistance Mutations: A Literature Review. (Pubmed Central) - Feb 23, 2024
The prevalence of drug resistance depends on the population tested, as well as the drug, and ranges from no mutations detected to up to almost 50%. A high prevalence of resistance emphasizes the importance of testing the patient whenever resistance is suspected, which requires the development of more sensitive and rapid tests while also highlighting the need for alternative therapeutic targets, strategies and the development of an effective vaccine.
- | Prevymis (letermovir) / Merck (MSD), Campath (alemtuzumab) / Sanofi
Trial primary completion date: Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab (clinicaltrials.gov) - Feb 15, 2024
P2, N=25, Recruiting, Sponsor: Ohio State University Comprehensive Cancer Center
A high prevalence of resistance emphasizes the importance of testing the patient whenever resistance is suspected, which requires the development of more sensitive and rapid tests while also highlighting the need for alternative therapeutic targets, strategies and the development of an effective vaccine. Trial primary completion date: Dec 2023 --> Dec 2024
- | Prevymis (letermovir) / Merck (MSD)
Enrollment change, Real-world evidence, Real-world: Letermovir Prophylaxis for CMV Infection in Haplo-HSCT Recipients: Single-center Data in China (clinicaltrials.gov) - Feb 15, 2024
P=N/A, N=200, Recruiting, Sponsor: The First Affiliated Hospital of Soochow University
Trial primary completion date: Dec 2023 --> Dec 2024 N=50 --> 200
- | Prevymis (letermovir) / Merck (MSD)
Phase classification: Letermovir Treatment in Pediatric Participants Following Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) (MK-8228-030) (clinicaltrials.gov) - Feb 15, 2024
P2, N=65, Completed, Sponsor: Merck Sharp & Dohme LLC
N=50 --> 200 Phase classification: P2b --> P2
- Prevymis (letermovir) / Merck (MSD)
USE OF LETERMOVIR IN PEDIATRIC POPULATION POST BONE MARROW TRANSPLANT (CLYDE) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2814;
Letermovir was well tolerated in all cases. Further studies are needed.
- Prevymis (letermovir) / Merck (MSD)
USE OF LETERMOVIR IN PEDIATRIC POPULATION POST BONE MARROW TRANSPLANT (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2813;
Letermovir was well tolerated in all cases. Further studies are needed.
- Prevymis (letermovir) / Merck (MSD)
USE OF LETERMOVIR IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS UNDER AGE OF 12: A RETROSPECTIVE MULTI-CENTRE STUDY ON BEHALF OF THE IEWP AND PDWP (CLYDE) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2812;
Breakthrough reactivations/infections were infrequent and very well treatable. Consequently, the success of CMV prophylaxis with letermovir for children and infants below 12 years of age warrants licensing of this drug in due time.
- Prevymis (letermovir) / Merck (MSD)
USE OF LETERMOVIR IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS UNDER AGE OF 12: A RETROSPECTIVE MULTI-CENTRE STUDY ON BEHALF OF THE IEWP AND PDWP (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2811;
Breakthrough reactivations/infections were infrequent and very well treatable. Consequently, the success of CMV prophylaxis with letermovir for children and infants below 12 years of age warrants licensing of this drug in due time.
- Prevymis (letermovir) / Merck (MSD), Rituxan (rituximab) / Roche
UPDATE ON DONOR DERIVED NK CELLS INFUSION FOLLOWING HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANT IN PEDIATRIC HIGH-RISK AND RELAPSED/REFRACTORY LEUKEMIA (CLYDE) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2800;
Donor NKs infusion after haplo-HSCT could represent an effective option to improve transplant outcome and prevent virus reactivation in pediatric patients with high-risk leukemia. However, these promising preliminary results need to be confirmed in larger cohorts.
- Prevymis (letermovir) / Merck (MSD), Rituxan (rituximab) / Roche
UPDATE ON DONOR DERIVED NK CELLS INFUSION FOLLOWING HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANT IN PEDIATRIC HIGH-RISK AND RELAPSED/REFRACTORY LEUKEMIA (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2799;
Donor NKs infusion after haplo-HSCT could represent an effective option to improve transplant outcome and prevent virus reactivation in pediatric patients with high-risk leukemia. However, these promising preliminary results need to be confirmed in larger cohorts.
- Prevymis (letermovir) / Merck (MSD)
TRIPLEX VACCINE TO INDUCE PROTECTIVE AND DURABLE CYTOMEGALOVIRUS-SPECIFIC CELLULAR IMMUNITY IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS AT RISK FOR CYTOMEGALOVIRUS COMPLICATIONS (Hall 3 South) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2785;
Triplex vaccination can overcome the letermovir-induced immune impairment. Novel successful strategies of vaccinating the immunocompetent HCT donor and the recipient with Triplex may suffice to prevent CMV reactivation by promoting early post-HCT sustained, protective CMV-immune reconstitution
- fludarabine IV / Generic mfg., busulfan / Generic mfg.
THE COMBINATION OF FLUDARABINE, BUSULFAN AND ANTI-T LYMPHOCYTE GLOBULIN IS WELL TOLERATED AND OFFERS EFFECTIVE REDUCED INTENSITY CONDITIONING THERAPY FOR PATIENTS WITH MYELOID DISEASE (CLYDE) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2638;
With a 2-year RFS of over 60%, it similarly offers effective disease treatment for older patients with myeloid disease, particularly when combined with judicious use of DLI. The regimen is well suited to elderly patients over the age of 65, although improvements in relapse risk and immune reconstitution justify a trial of reduced ATLG dosing.
- fludarabine IV / Generic mfg., busulfan / Generic mfg.
THE COMBINATION OF FLUDARABINE, BUSULFAN AND ANTI-T LYMPHOCYTE GLOBULIN IS WELL TOLERATED AND OFFERS EFFECTIVE REDUCED INTENSITY CONDITIONING THERAPY FOR PATIENTS WITH MYELOID DISEASE (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2637;
With a 2-year RFS of over 60%, it similarly offers effective disease treatment for older patients with myeloid disease, particularly when combined with judicious use of DLI. The regimen is well suited to elderly patients over the age of 65, although improvements in relapse risk and immune reconstitution justify a trial of reduced ATLG dosing.
- Prevymis (letermovir) / Merck (MSD), Valcyte (valganciclovir) / Roche, Mitsubishi Tanabe, Cytovene (ganciclovir) / Roche
REAL-WORLD OUTCOMES AND TREATMENT PATTERNS OF CMV INFECTIONS IN HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS, REFRACTORY OR INTOLERANT TO TREATMENTS IN EUROPE, CANADA, ISRAEL: INTERIM ANALYSIS (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2401;
This interim analysis highlights the real-world burden of CMV infection/disease for HSCT recipients and illustrates limitations of current standard of care for managing RRI CMV and the need for improved treatments. A notable proportion of patients experienced adverse events of myelosuppression and nephrotoxicity; these results are consistent with those from prior studies in this patient population
- PHYSICIAN PERSPECTIVES ON THE BURDEN AND CLINICAL MANAGEMENT OF CYTOMEGALOVIRUS (CMV) INFECTION IN TRANSPLANT RECIPIENTS IN CENTRAL AND EASTERN EUROPE (CLYDE) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2265;
Physicians reported intravenous ganciclovir and oral valganciclovir to be completely associated with rapid clearance of viraemia (32.3%) and convenient administration (37.8%), respectively, in transplant recipients with refractory PT-CMV infection...Approximately half of physicians reported having limited experience with newer anti-CMV options, such as treatment with maribavir (54.9%) and prophylaxis with letermovir (50.6%) (Figure 1)... This study provides real-world evidence from Central and Eastern Europe, bridging an existing knowledge gap and providing crucial epidemiological data on the prevalence, treatment practices and physicians
- PHYSICIAN PERSPECTIVES ON THE BURDEN AND CLINICAL MANAGEMENT OF CYTOMEGALOVIRUS (CMV) INFECTION IN TRANSPLANT RECIPIENTS IN CENTRAL AND EASTERN EUROPE (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2264;
Physicians reported intravenous ganciclovir and oral valganciclovir to be completely associated with rapid clearance of viraemia (32.3%) and convenient administration (37.8%), respectively, in transplant recipients with refractory PT-CMV infection...Approximately half of physicians reported having limited experience with newer anti-CMV options, such as treatment with maribavir (54.9%) and prophylaxis with letermovir (50.6%) (Figure 1)... This study provides real-world evidence from Central and Eastern Europe, bridging an existing knowledge gap and providing crucial epidemiological data on the prevalence, treatment practices and physicians
- Prevymis (letermovir) / Merck (MSD)
PHARMACEUTICAL INTERVENTIONS WITHIN A BMT/ CART PREHABILITATION SERVICE (GALA) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2243;
Pharmaceutical considerations were often multifactorial, particularly in the CART cohort and required a holistic review of overall management. Translation of interventions into clinical practice is supported by pharmacist prescribing of the admission drug chart.
- Prevymis (letermovir) / Merck (MSD)
OUTCOME OF THE USE OF LETERMOVIR AS PROPHYACTIC TREATMENT FOR HSCT RECIPIENTS: A SINGLE CENTER EXPERIENCE (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2148;
Treatment relies upon anti-CMV specific Immunoglobulin and antiviral drugs such as Ganciclovir, Foscavir or Cidofovir. The experience of our center shows an efficacy of the prophylactic use of letermovir in patients undergoing HSCT, even if it showed reactivation events which, overall, allowed effective therapeutic management with rapid resolution without complications.
- Prevymis (letermovir) / Merck (MSD)
NO INFERIOR OUTCOME OF OMITTING FLUOROQUINOLONE PROPHYLAXIS IN PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2057;
Omitting FC prophylaxis did not have a negative impact on OS, BSI or CDI. Superior OS is most likely explained by confounding factors such as the new approval of drugs
- Prevymis (letermovir) / Merck (MSD), Campath (alemtuzumab) / Sanofi, Jakafi (ruxolitinib) / Novartis, Incyte
MONITORING OF CMV-SPECIFIC CELL-MEDIATED IMMUNITY - PROGNOSTIC FACTORS AND CLINICAL VALUE (CLYDE) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2017;
Superior OS is most likely explained by confounding factors such as the new approval of drugs 8 patients received no TCD.CMV-serostatus: Donor(D)+/recipient(R)+ in 125, D+/R- in 11, D-/R+ in 34 and D-/R- in 3 patients.All CMVpos recipients received Letermovir prophylaxis until d+100...In most of them immunosuppression was initiated after d+100: 20/28 (71%) high dose corticosteroids, 1/28 (4%) Ruxolitinib.Excluding patients, that received additional immunosuppression after d+100 only 7/89 (8%) developed a CMV reactivation despite a positive d+100 T-Track
- Prevymis (letermovir) / Merck (MSD), Campath (alemtuzumab) / Sanofi, Jakafi (ruxolitinib) / Novartis, Incyte
MONITORING OF CMV-SPECIFIC CELL-MEDIATED IMMUNITY - PROGNOSTIC FACTORS AND CLINICAL VALUE (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_2016;
8 patients received no TCD.CMV-serostatus: Donor(D)+/recipient(R)+ in 125, D+/R- in 11, D-/R+ in 34 and D-/R- in 3 patients.All CMVpos recipients received Letermovir prophylaxis until d+100...In most of them immunosuppression was initiated after d+100: 20/28 (71%) high dose corticosteroids, 1/28 (4%) Ruxolitinib.Excluding patients, that received additional immunosuppression after d+100 only 7/89 (8%) developed a CMV reactivation despite a positive d+100 T-Track 8 patients received no TCD.CMV-serostatus: Donor(D)+/recipient(R)+ in 125, D+/R- in 11, D-/R+ in 34 and D-/R- in 3 patients.All CMVpos recipients received Letermovir prophylaxis until d+100...In most of them immunosuppression was initiated after d+100: 20/28 (71%) high dose corticosteroids, 1/28 (4%) Ruxolitinib.Excluding patients, that received additional immunosuppression after d+100 only 7/89 (8%) developed a CMV reactivation despite a positive d+100 T-Track
- Prevymis (letermovir) / Merck (MSD)
LETERMOVIR PROPHYLAXIS REDUCED CYTOMEGALOVIRUS REACTIVATION AND RESISTANCE POST UMBILICAL CORD BLOOD TRANSPLANTATION (CLYDE) - Feb 14, 2024 - Abstract #EBMT2024EBMT_1924;
8 patients received no TCD.CMV-serostatus: Donor(D)+/recipient(R)+ in 125, D+/R- in 11, D-/R+ in 34 and D-/R- in 3 patients.All CMVpos recipients received Letermovir prophylaxis until d+100...In most of them immunosuppression was initiated after d+100: 20/28 (71%) high dose corticosteroids, 1/28 (4%) Ruxolitinib.Excluding patients, that received additional immunosuppression after d+100 only 7/89 (8%) developed a CMV reactivation despite a positive d+100 T-Track LET has great potential in reducing CMV reactivation and resistance post UCBT in the future, and it is well worth exploring the optimal withdrawal time and high-risk population of LET prophylaxis in the future.
- Prevymis (letermovir) / Merck (MSD)
LETERMOVIR PROPHYLAXIS REDUCED CYTOMEGALOVIRUS REACTIVATION AND RESISTANCE POST UMBILICAL CORD BLOOD TRANSPLANTATION (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_1923;
LET has great potential in reducing CMV reactivation and resistance post UCBT in the future, and it is well worth exploring the optimal withdrawal time and high-risk population of LET prophylaxis in the future. LET has great potential in reducing CMV reactivation and resistance post UCBT in the future, and it is well worth exploring the optimal withdrawal time and high-risk population of LET prophylaxis in the future.
- Prevymis (letermovir) / Merck (MSD)
LETERMOVIR PROPHYLAXIS FOR CYTOMEGALOVIRUS INFECTION IS THE POTENTIAL RISK OF EBV-POSITIVE POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDERS AFTER HAPLOIDENTICAL STEM-CELL TRANSPLANTATION (CLYDE) - Feb 14, 2024 - Abstract #EBMT2024EBMT_1922;
LET has great potential in reducing CMV reactivation and resistance post UCBT in the future, and it is well worth exploring the optimal withdrawal time and high-risk population of LET prophylaxis in the future. Our findings demonstrate that prophylactic letermovir treatment is highly effective in reducing the risk of CMV-related complications, but is the potential risk of EBV-positive PLTD after haplo-SCT.
- Prevymis (letermovir) / Merck (MSD)
LETERMOVIR PROPHYLAXIS FOR CYTOMEGALOVIRUS INFECTION IS THE POTENTIAL RISK OF EBV-POSITIVE POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDERS AFTER HAPLOIDENTICAL STEM-CELL TRANSPLANTATION (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_1921;
Our findings demonstrate that prophylactic letermovir treatment is highly effective in reducing the risk of CMV-related complications, but is the potential risk of EBV-positive PLTD after haplo-SCT. Our findings demonstrate that prophylactic letermovir treatment is highly effective in reducing the risk of CMV-related complications, but is the potential risk of EBV-positive PLTD after haplo-SCT.
- Prevymis (letermovir) / Merck (MSD)
LETERMOVIR IS SAFE AND EFFECTIVE FOR TREATMENT AND PREVENTION OF CMV REACTIVATION IN PAEDIATRIC ALLOGENEIC STEM CELL TRANSPLANT (CLYDE) - Feb 14, 2024 - Abstract #EBMT2024EBMT_1920;
In our cohort using Letermovir as prophylaxis decreases duration of therapy, decreases therapy failure, and had better long term outcomes. As a treatment where other therapies have failed it can induce responses, including in CNS disease.
- Prevymis (letermovir) / Merck (MSD)
LETERMOVIR IS SAFE AND EFFECTIVE FOR TREATMENT AND PREVENTION OF CMV REACTIVATION IN PAEDIATRIC ALLOGENEIC STEM CELL TRANSPLANT (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_1919;
In our cohort using Letermovir as prophylaxis decreases duration of therapy, decreases therapy failure, and had better long term outcomes. As a treatment where other therapies have failed it can induce responses, including in CNS disease.
- Prevymis (letermovir) / Merck (MSD), Cytovene (ganciclovir) / Roche
LETERMOVIR COMBINED WITH GANCICLOVIR AS A PREEMPTIVE OR TREATMENT FOR CYTOMEGALOVIRUS INFECTION FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, A SINGLE-CENTER RETROSPECTIVE REVIEW (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_1918;
Ganciclovir at an tapered dose in combination with letemovir is efficient, particularly in reducing the duration of infection and preventing the poor prognosis that followed. In terms of safety, this regimen helps lessen the harm that conventional treatment causes to the liver, kidneys, and severe hematologic toxicity.
- Prevymis (letermovir) / Merck (MSD)
LETERMOVIR AS TREATMENT AND SECONDARY PROPHYLAXIS OF CMV REACTIVATION IN LOW-WEIGHT PEDIATRIC PATIENTS (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_1917;
Due to the well-known toxicity of such drug, a switch to a better tolerated treatment was needed. The use of Letermovir once virological drop was achieved, showed to be safe and effective in inducing and maintaining CMV negativity, preventing further reactivation at the last available follow-up.
- Prevymis (letermovir) / Merck (MSD), Cytovene (ganciclovir) / Roche, Entyvio (vedolizumab) / Takeda
IS THERE A PLACE FOR ANTI-HCMV HUMAN IMMUNOGLOBULIN AS PRE-EMPTIVE THERAPY IN T-DEPLETE TREG/TCON ALLOGENEIC STEM CELL TRANSPLANTATION? (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_1897;
There are evidence of a specific stimulatory effect on T-CD4+ and T-CD8+, but further studies are needed. The presented 2 cases had frailties that made unsafe the use of Ganciclovir or Foscarnet.
- Prevymis (letermovir) / Merck (MSD), Valcyte (valganciclovir) / Roche, Mitsubishi Tanabe
IMPACT OF QUANTIFERON-CMV (QNF-CMV) ON LATE ONSET CLINICALLY SIGNIFICANT CMV INFECTION (CSCMVI) AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) (CLYDE) - Feb 14, 2024 - Abstract #EBMT2024EBMT_1789;
QNF-CMV may represent a useful tool to predict post transplant specific immune reconstitution against CMV, potentially leading to risk-adapted therapeutic decisions. Additional prospective studies are needed to confirm these data.
- Prevymis (letermovir) / Merck (MSD), Valcyte (valganciclovir) / Roche, Mitsubishi Tanabe
IMPACT OF QUANTIFERON-CMV (QNF-CMV) ON LATE ONSET CLINICALLY SIGNIFICANT CMV INFECTION (CSCMVI) AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_1788;
QNF-CMV may represent a useful tool to predict post transplant specific immune reconstitution against CMV, potentially leading to risk-adapted therapeutic decisions. Additional prospective studies are needed to confirm these data.
- Prevymis (letermovir) / Merck (MSD)
IMPACT OF LETERMOVIR PRIMARY AND SECONDARY PROPHYLAXIS IN A PEDIATRIC COHORT (CLYDE) - Feb 14, 2024 - Abstract #EBMT2024EBMT_1779;
Letermovir proved to be effective as both primary and secondary prophylaxis in preventing CMV infection and was well tolerated in pediatric patients. Our results suggest that letermovir effectively reduces CMV reactivation events in high-risk patients.
- Prevymis (letermovir) / Merck (MSD)
IMPACT OF LETERMOVIR PRIMARY AND SECONDARY PROPHYLAXIS IN A PEDIATRIC COHORT (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_1778;
Letermovir proved to be effective as both primary and secondary prophylaxis in preventing CMV infection and was well tolerated in pediatric patients. Our results suggest that letermovir effectively reduces CMV reactivation events in high-risk patients.
- Prevymis (letermovir) / Merck (MSD)
IMMUNE POPULATIONS PREDICT CONTROL OF CMV REACTIVATION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (CLYDE) - Feb 14, 2024 - Abstract #EBMT2024EBMT_1732;
We have designed and cross-validated a highly accurate model capable of stratifying patients within NR, VC and VNC in the first 100 days after alloHSCT. This may aid in anticipating CMV reactivation and its need for treatment with the consequent benefit for the patients
- Prevymis (letermovir) / Merck (MSD)
IMMUNE POPULATIONS PREDICT CONTROL OF CMV REACTIVATION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_1731;
We have designed and cross-validated a highly accurate model capable of stratifying patients within NR, VC and VNC in the first 100 days after alloHSCT. This may aid in anticipating CMV reactivation and its need for treatment with the consequent benefit for the patients
- Simulect (basiliximab) / Novartis, Prevymis (letermovir) / Merck (MSD)
GVHD PROPHYLAXIS WITH THREE VERSUS FIVE DRUGS COMBINATION IN AML PATIENTS UNDERGOING ALLOGENEIC TRANSPLANT FROM HLA MISMATCHED UNRELATED OR HAPLOIDENTICAL RELATED DONOR (CLYDE) - Feb 14, 2024 - Abstract #EBMT2024EBMT_1608;
Although, comparing the two cohorts no significative impact on 100days, 1year-NRM and OS was observed, the 3 drugs combination seems more protective against the aGVHD occurrence (41% versus 13%; p= 0.01). However, an in depth-extension of the analysis is in progress.
- Simulect (basiliximab) / Novartis, Prevymis (letermovir) / Merck (MSD)
GVHD PROPHYLAXIS WITH THREE VERSUS FIVE DRUGS COMBINATION IN AML PATIENTS UNDERGOING ALLOGENEIC TRANSPLANT FROM HLA MISMATCHED UNRELATED OR HAPLOIDENTICAL RELATED DONOR (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_1607;
Although, comparing the two cohorts no significative impact on 100days, 1year-NRM and OS was observed, the 3 drugs combination seems more protective against the aGVHD occurrence (41% versus 13%; p= 0.01). However, an in depth-extension of the analysis is in progress.
- Livtencity (maribavir) / Takeda, GSK
EXPERIENCE WITH THE USE OF MARIBAVIR IN HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS WITH REFRACTORY OR RESISTANT CYTOMEGALOVIRUS (CMV) (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_1502;
In our center, we observed that Maribavir is an effective drug for clearing CMV viremia in HSCT recipients with refractory or resistant CMV, with a good safety profile. The drug's rapid action, as observed in our center compared to the literature, has led to its good acceptance and adherence by the patients themselves.
- Prevymis (letermovir) / Merck (MSD)
EPSTEIN-BARR VIRUS-RELATED POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDERS IN THE LETERMOVIR ERA (CLYDE) - Feb 14, 2024 - Abstract #EBMT2024EBMT_1457;
EBV reactivation promoted the recovery of the immune response. The immune response was significantly impaired in patients with EBV-related PTLD.?
- Prevymis (letermovir) / Merck (MSD)
EPSTEIN-BARR VIRUS-RELATED POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDERS IN THE LETERMOVIR ERA (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_1456;
EBV reactivation promoted the recovery of the immune response. The immune response was significantly impaired in patients with EBV-related PTLD.?
- Prevymis (letermovir) / Merck (MSD), Cytovene (ganciclovir) / Roche
EPIDEMIOLOGY, CLINICAL OUTCOMES AND TREATMENT PATTERNS OF CYTOMEGALOVIRUS (CMV) INFECTION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHINA: A SCOPING REVIEW AND META-ANALYSIS (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_1450;
Clinical data in Chinese populations are limited at present. Results demonstrate that the management of CMV mainly focused on pre-emptive therapy due to the treatment limited toxicity of anti-CMV agents.
- EPIDEMIOLOGY OF VIRAEMIA IN CHILDREN UNDERGOING CORD BLOOD STEM CELL TRANSPLANT (CB-SCT) WITH NON-MALIGNANT DISEASES: A RETROSPECTIVE COHORT STUDY (CLYDE) - Feb 14, 2024 - Abstract #EBMT2024EBMT_1449;
Single anti-viral (ganciclovir/valganciclovir) was effective in 4/9 cases while Foscarnet was required as a second ant-viral agent in 5/9 cases...Four of these viremia episodes were treated with cidofovir, administered as 1 mg/kg three times a week therapy and oral brincidofovir was given successfully to one patient...Excellent response was seen as the child completely cleared EBV after a single dose of rituximab... This retrospective cohort from a single centre reports that despite T-cell depletion and with CB infused T-cells being na